Can anesthesia hide the trip? new study tests psilocybin for depression without the psychedelic experience

NCT ID NCT07479550

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving psilocybin—a psychedelic drug being studied for depression—under general anesthesia can hide its mind-altering effects. That would allow researchers to run a truly blinded trial where neither patients nor doctors know who got the real drug. Ten adults with major depression will receive either psilocybin or placebo during four sessions of anesthesia. The main goal is to see if the blinding works and if the approach is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
psilocybin (a psychedelic compound) given under general anesthesia with propofol
What this could lead to
If this approach works, it could enable fully blinded studies of psychedelics, improving the reliability of research into depression treatments.
What could go wrong
This is a very small early-phase trial (10 people) focused on feasibility and blinding, not on proving effectiveness. The added risks of general anesthesia and the unknown effect of masking the psychedelic experience may limit its success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stanford University

    Stanford, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.